Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

NCT02561988 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT02561988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02561988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1
Overall status
Completed
Start date
March 10, 2016
Completion date
January 19, 2023
Enrollment
86 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive systemic mastocytosis, mast cell leukemia, relapsed or refractory myeloid malignancies, systemic mastocytosis-associated hematologic non-mast cell disease